AGIO Agios Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: AGIO

Price (delayed)

$21.74

Market cap

$1.2B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.23

Enterprise value

$1.15B

Agios is focused on discovering and developing novel investigational medicines to treat malignant hematology, solid tumors and rare genetic diseases through scientific leadership in the field of cellular metabolism. In ...

Highlights
Agios Pharmaceuticals's gross profit has increased by 45% QoQ
The revenue has grown by 43% since the previous quarter
Agios Pharmaceuticals's EPS has shrunk by 116% YoY but it has increased by 24% QoQ
AGIO's net income has shrunk by 114% YoY but it is up by 36% QoQ
The quick ratio is down by 27% year-on-year and by 8% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.agios.com
Peers: XNCR EXEL BMRN PFE

Key stats

What are the main financial stats of AGIO
Market
Shares outstanding
55.29M
Market cap
$1.2B
Enterprise value
$1.15B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.09
Price to sales (P/S)
83.65
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
80.64
Earnings
Revenue
$14.24M
EBIT
-$231.8M
EBITDA
-$213.24M
Free cash flow
-$313.4M
Per share
EPS
-$4.23
Free cash flow per share
-$5.72
Book value per share
$20.03
Revenue per share
$0.26
TBVPS
$22.61
Balance sheet
Total assets
$1.24B
Total liabilities
$137.9M
Debt
$85.66M
Equity
$1.1B
Working capital
$770.14M
Liquidity
Debt to equity
0.08
Current ratio
13.3
Quick ratio
12.54
Net debt/EBITDA
0.25
Margins
EBITDA margin
-1,497.5%
Gross margin
88%
Net margin
-1,627.8%
Operating margin
-1,765%
Efficiency
Return on assets
-18.5%
Return on equity
-20.7%
Return on invested capital
-19.6%
Return on capital employed
-19.7%
Return on sales
-1,627.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AGIO stock price

How has the Agios Pharmaceuticals stock price performed over time
Intraday
-1.09%
1 week
-6.53%
1 month
-13.42%
1 year
-26.95%
YTD
-22.58%
QTD
-22.58%

Financial performance

How have Agios Pharmaceuticals's revenue and profit performed over time
Revenue
$14.24M
Gross profit
$12.54M
Operating income
-$251.34M
Net income
-$231.8M
Gross margin
88%
Net margin
-1,627.8%
AGIO's net income has shrunk by 114% YoY but it is up by 36% QoQ
The net margin has surged by 55% since the previous quarter
The operating margin has surged by 54% since the previous quarter
Agios Pharmaceuticals's gross profit has increased by 45% QoQ

Growth

What is Agios Pharmaceuticals's growth rate over time

Valuation

What is Agios Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.09
P/S
83.65
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
80.64
Agios Pharmaceuticals's EPS has shrunk by 116% YoY but it has increased by 24% QoQ
The P/B is 72% below the 5-year quarterly average of 3.9 and 16% below the last 4 quarters average of 1.3
Agios Pharmaceuticals's equity has decreased by 15% YoY but it has increased by 4.8% QoQ
AGIO's P/S is 86% below its last 4 quarters average of 590.6
The revenue has grown by 43% since the previous quarter

Efficiency

How efficient is Agios Pharmaceuticals business performance
AGIO's return on equity has dropped by 122% year-on-year but it is up by 33% since the previous quarter
The ROA has plunged by 121% YoY but it has grown by 34% from the previous quarter
The company's return on invested capital has shrunk by 112% YoY but it rose by 34% QoQ
Agios Pharmaceuticals's return on sales has surged by 56% QoQ

Dividends

What is AGIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AGIO.

Financial health

How did Agios Pharmaceuticals financials performed over time
The quick ratio is down by 27% year-on-year and by 8% since the previous quarter
AGIO's current ratio is down by 25% year-on-year and by 9% since the previous quarter
The debt is 92% smaller than the equity
Agios Pharmaceuticals's equity has decreased by 15% YoY but it has increased by 4.8% QoQ
The debt has declined by 12% year-on-year and by 3.7% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.